HumGel
MyoGel™ — a hydrogel extracted from benign human leiomyoma tissue, replacing Matrigel (which comes from mouse sarcoma) in 3D cell culture and drug testing, and stable at room temperature. Developed in Professor Tuula Salo's laboratory at the University of Oulu: the work began in 2009 with cancer cells cultured on myoma discs and reached gel form in 2015, with a substantial peer-reviewed record behind it. Registered address on the Oulu university campus.
The row
- Stage
- Pre-revenue — No sales yet
- Location
- Oulu
- Founded
- 2026
- Research origin
- Univ. of Oulu
- Business ID
- 3591410-1 · Finnish trade register
- Funding
- No funding round disclosed; in the Health Incubator Helsinki programme
Links
Where this sits on the map
HumGel is one of 33 companies in Therapeutics & Diagnostics. The others:
How this row was decided
Every row on this map is checked by hand against the trade register and the company's own material, and placed in the sector that best describes its business or its technology. Service firms and consultancies are left out, however advanced the technology they work with — the test is where the revenue comes from. Only funding figures the company or its investor has published are shown. The full rules are on the landscape ↗